BFC Planning’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.4K Buy
135
+50
+59% +$1.73K ﹤0.01% 2737
2026
Q2
$3.32K Buy
85
+60
+240% +$1.94K ﹤0.01% 2836
2026
Q1
$814 Hold
25
– – ﹤0.01% 2776
2025
Q4
$880 Sell
25
-30
-55% -$1.06K ﹤0.01% 2822
2025
Q3
$1.44K Hold
55
– – ﹤0.01% 2558
2025
Q2
$1.46K Buy
55
+25
+83% +$658 ﹤0.01% 2379
2025
Q1
$724 Sell
30
-138
-82% -$4.36K ﹤0.01% 2486
2024
Q4
$6.76K Hold
168
– – ﹤0.01% 1920
2024
Q3
$10.6K Buy
+168
New +$9.9K ﹤0.01% 1718

Other funds holding VKTX

BFC Planning's VKTX Position: Q3 2026 in Review

BFC Planning increased its Viking Therapeutics (VKTX) stake by 59% in Q3 2026, buying an estimated $1.73K and bringing the position to 135 shares worth $4.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2737.

BFC Planning first reported a position in VKTX in Q3 2024 and has held it in 9 quarters since. The position peaked at $10.6K in Q3 2024. 330 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • BFC Planning held 135 shares of Viking Therapeutics worth $4.4K as of Q3 2026.
  • BFC Planning bought 50 Viking Therapeutics shares in Q3 2026, an estimated $1.73K.
  • Viking Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2737 holding.
  • BFC Planning first reported a position in Viking Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Viking Therapeutics position peaked at $10.6K in Q3 2024.
  • 330 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.